Literature DB >> 23523089

Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial.

R W Blamey1, T Bates, U Chetty, S W Duffy, I O Ellis, D George, E Mallon, M J Mitchell, I Monypenny, D A L Morgan, R D Macmillan, J Patnick, S E Pinder.   

Abstract

BACKGROUND: The incidence of local recurrence (LR) after conservative surgery for early breast cancer without adjuvant therapy is unacceptably high even with favourable tumours. The aim of this study was to examine the effect of adjuvant therapies in tumours with excellent prognostic features.
METHODS: Patients with primary invasive breast cancer <2 cm diameter, grade 1 or good prognosis special type, and node negative, treated by wide local excision (WLE) with clear margins were randomised into a 2 × 2 clinical trial of factorial design with or without radiotherapy and with or without tamoxifen. Trial entry was allowed to either comparison or both.
FINDINGS: The actuarial breast cancer specific survival in 1135 randomised patients at 10 years was 96%. Analysis by intention to treat showed that LR after WLE was reduced in patients randomised to radiotherapy (RT) (HR 0.37, CI 0.22-0.61 p<0.001) and to tamoxifen (HR 0.33, CI 0.15 - 0.70 p<0.004). Actuarial analysis of patients entered into the four-way randomisation showed that LR after WLE alone was 1.9% per annum (PA) versus 0.7% with RT alone and 0.8% with tamoxifen alone. No patient randomised to both adjuvant treatments developed LR. Analysis by treatment received showed LR at 2.2%PA for surgery alone versus 0.8% for either adjuvant radiotherapy or tamoxifen and 0.2% for both treatments.
CONCLUSIONS: Even in these patients with tumours of excellent prognosis, LR after conservative surgery without adjuvant therapy was still very high. This was reduced to a similar extent by either radiotherapy or tamoxifen but to a greater extent by the receipt of both treatments.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23523089     DOI: 10.1016/j.ejca.2013.02.031

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  41 in total

Review 1.  Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

Authors:  O C Freedman; G G Fletcher; S Gandhi; M Mates; S F Dent; M E Trudeau; A Eisen
Journal:  Curr Oncol       Date:  2015-03       Impact factor: 3.677

2.  [Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer].

Authors:  Marciana Nona Duma
Journal:  Strahlenther Onkol       Date:  2018-11       Impact factor: 3.621

3.  Treatment Strategies in Octogenarians with Early-Stage, High-Risk Breast Cancer.

Authors:  Anita Mamtani; Julie J Gonzalez; Dayna T Neo; Robb S Friedman; Abram Recht; Michele R Hacker; Ranjna Sharma
Journal:  Ann Surg Oncol       Date:  2018-02-09       Impact factor: 5.344

4.  [Critical consideration of ipsilateral axillary recurrence after breast conservative surgery and the protective effect of whole breast radiotherapy].

Authors:  Frederik Wenz; Elena Sperk
Journal:  Strahlenther Onkol       Date:  2017-11       Impact factor: 3.621

Review 5.  De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients.

Authors:  Pierfrancesco Franco; Giuseppe Carlo Iorio; Sara Bartoncini; Mario Airoldi; Corrado De Sanctis; Isabella Castellano; Umberto Ricardi
Journal:  Med Oncol       Date:  2018-04-03       Impact factor: 3.064

Review 6.  De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer.

Authors:  E Shelley Hwang; Lawrence Solin
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 44.544

7.  The Screening, Diagnosis, Treatment, and Follow-Up of Breast Cancer.

Authors:  Achim Wöckel; Ute-Susann Albert; Wolfgang Janni; Anton Scharl; Rolf Kreienberg; Tanja Stüber
Journal:  Dtsch Arztebl Int       Date:  2018-05-04       Impact factor: 5.594

8.  Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer.

Authors:  Chelain R Goodman; Brandon-Luke L Seagle; Thomas W P Friedl; Brigitte Rack; Krisztian Lato; Visnja Fink; Massimo Cristofanilli; Eric D Donnelly; Wolfgang Janni; Shohreh Shahabi; Jonathan B Strauss
Journal:  JAMA Oncol       Date:  2018-08-09       Impact factor: 31.777

Review 9.  Evolution of radiotherapy techniques in breast conservation treatment.

Authors:  John Boyages; Lesley Baker
Journal:  Gland Surg       Date:  2018-12

10.  Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.

Authors:  Kevin S Hughes; Lauren A Schnaper; Jennifer R Bellon; Constance T Cirrincione; Donald A Berry; Beryl McCormick; Hyman B Muss; Barbara L Smith; Clifford A Hudis; Eric P Winer; William C Wood
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.